Malka Berro
Policy Associate
Senators Jerry Moran (R-KS) and Jon Tester (D-MT) spoke at a Washington Post Live event this week about veterans’ mental health and their new bill, the Commander John Scott Hannon Veterans Mental Health Care Improvement Act (S. 785). On average, 20 veterans die by suicide every day, with only 6 of those having received treatment […]
Malka Berro
Policy Associate
Last week, the Drug Enforcement Administration (DEA) officially missed its deadline to submit its plans to Congress on how it will execute a special registration process that would allow providers to prescribe controlled substances via telemedicine. The directive from Congress was passed in last year’s SUPPORT for Patients and Communities Act and was aimed at combatting the opioid crisis by increasing access to medication-assisted treatment (MAT). DEA was given one year from the signing of that law to create and release its plan to initiate this special registration process. While the agency admits it missed the deadline, no plans have yet been announced to comply with the law and finalize the special registration process.
Michael Petruzzelli
Director, Federal Policy and Advocacy
New legislation introduced in Congress this week would expand access to telemedicine for mental health and substance use disorder treatment. The Improving Access to Remote Behavioral Health Treatment Act of 2019 (S. 2244/H.R. 4131) would amend regulations for the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 and specifically name community mental health centers and addiction treatment centers as eligible sites to prescribe controlled substances via telemedicine.
Stephanie Pellitt
, National Council for Behavioral Health
The National Council has been a longtime advocate for changing federal regulations that restrict how behavioral health medications that are controlled substances can be prescribed via telemedicine. Recognizing the urgent need to expand access to medication-assisted treatment (MAT) and other behavioral health medications, the National Council worked closely with Members of Congress to secure a provision in the opioid legislative package (SUPPORT Act) that would address this problem. The Drug Enforcement Administration (DEA) now has until October 1, 2019 to clarify when the agency can issue prescribers a special registration that would enable them to treat patients for the first time via telemedicine.
Shelley Starkey
New provisions that would expand access to medication-assisted treatment (MAT) via telemedicine were included in the sweeping package of opioid legislation (H.R. 6) that has been passed by Congress and now awaits the President’s signature. The National Council for Behavioral Health applauds Congress for acting on this issue and taking up our recommendations, and remains committed to further expanding access to these evidence-based treatments through telemedicine.
Michael Petruzzelli
, National Council for Behavioral Health
Last month, the Department of Health and Human Services and the Drug Enforcement Administration (DEA) jointly released guidance on telemedicine and the prescribing of opioids for treatment of opioid use disorder. The National Council has long been advocating for changes to be made to DEA regulations restricting how behavioral health medications that are controlled substances can be prescribed via telemedicine. While the guidance is meant to promote the use of telemedicine during the opioid crisis, it offers little “new” information and instead reiterates what is and is not permitted under current law.
